New Scientific Strategy In The Quest For An HIV Cure

Amid growing optimism that an HIV cure can be found, 34 leading HIV scientists and clinicians Friday launched what they termed a “Global Scientific Strategy Towards an HIV Cure” on behalf of the International AIDS Society (IAS) in Washington DC ahead of the 19th International AIDS Conference.

The vision is that a safe, affordable and scalable cure for HIV would improve the health and quality of life for those with living with the infection and reduce the risk of transmission to those not infected. The strategy identifies seven important priority areas for basic, translational and clinical research and maps out a path for future research, collaboration and funding opportunities.

“The strategy is the result of a collaborative effort which has produced a roadmap that will constructively move HIV Cure research forward,” said Françoise Barré-Sinoussi, the co-discoverer of HIV and Director of the Regulation of Retroviral Infections Unit at the Institut Pasteur in Paris and the IAS President-Elect.

Major investments in science have resulted in the worldwide availability of more than 20 anti-HIV drugs which can restore health, prolong life and reduce transmission of the virus. HIV-infected individuals who have access to antiretroviral drugs, and who are able to adhere to therapy can maintain control of HIV infection indefinitely. Despite these successes, these therapies cannot eradicate HIV, requiring people to remain on expensive and potentially toxic drugs for life and also remain prone to co-morbidities. Although the cost of delivering antiretroviral drugs to the more than 34 million people now living with the disease has decreased substantially, it is still overwhelmingly high. Estimates put the cost of the funding response to the HIV/AIDS epidemic by 2015 between US$22-24 billion per year and US$19-35 billion per year by 2031, with antiretroviral treatment accounting for up to 70 per cent of the total cost of care in the most affected countries.

Thus the search for an HIV Cure is an imperative in terms of the individual and public health benefits and an opportunity to potentially avoid the long-term cumulative costs of ART. An effective and scalable HIV cure is likely to stop transmission of HIV to those who are uninfected and restore the immunological function and normal health to those who are infected.

Many scientific advances are helping to shed light on why HIV persists. Scientists have known for some time that latent HIV reservoirs, where HIV hides and persists, are one of the main barriers to finding a cure. This is precisely why treatment does not eradicate HIV and when treatment is stopped, the virus rebounds.

For the first time, however, there is a “proof of concept,” for an effective cure. The case of Timothy Brown, the so-called “Berlin Patient,” who received a stem-cell bone-marrow transplant in 2007 and as he lacked CCR5, (the doorway through which HIV enters cells), is now considered to be cured of HIV and has got scientists thinking about the use of gene therapy to modify a patient’s own immune cells to make them resistant to HIV infection. The molecular biology regarding how HIV DNA becomes integrated in the chromosomes of infected people is the focus of intense research, wich has led to a number of possible interventions, some of which are being tested in the clinic. Recently, in a test in HIV+ patients, scientists have shown that a dose of a drug, that inhibits an enzyme involved in HIV silencing, leads to rapid production of HIV RNA in the patient’s latently infected cells. This could make such previously unreachable viral reservoirs susceptible to curative strategies. Scientists are also gaining a better understanding of a rare group of HIV infected people who appear to have naturally “cured” their own infection. These “elite controllers” are HIV positive but have no readily apparent virus in the blood. Scientists are.

There exists a unique cohort of patients in France who became HIV infected, started therapy early, and were able to successfully stop therapy without viral rebound (the “Visconti Cohort”). The study confirms the benefits of treating HIV at the very early stages of infection. Understanding this group of people, who efficiently control the virus replication and reservoirs, might lead to novel therapeutic interventions.

Currently, the following strategies are being investigated and it is expected that all of these strategies will be more efficient in combination with each other, alongside the use of antiretroviral therapy to at least protect the immune system of patients to prepare them for a cure: (i)Gene therapy; (ii)Treatment Optimization and Intensification (iii)Reversal of HIV; (iv) Immune-based Therapies and (v)Therapeutic Vaccination.

Strong community support is needed to advocate against complacency and to ensure that patients and their communities are fully engaged and informed about the risks and benefits of curative studies. “Under no circumstances should the inclusion of “cure” in the global response direct funding away from treatment, prevention and care programs, or from biomedical research on HIV and its consequences, including vaccine and other prevention research,” said Barré-Sinoussi. “However, it is imperative that donors, governments and the AIDS community make viable economic investment in HIV cure research, and right now.” (CNS).

(Shobha Shukla is the Managing Editor of Citizen News Service. Email: shobha@citizen-news.org, website: http://www.citizen-news.org).